Search

Your search keyword '"Benucci,Maurizio"' showing total 657 results
Start Over Author "Benucci,Maurizio"
657 results on '"Benucci,Maurizio"'

2. ToRaRI (Tofacitinib in Rheumatoid Arthritis a Real-Life experience in Italy): Effectiveness, safety profile of tofacitinib and concordance between patient-reported outcomes and physician's global assessment of disease activity in a retrospective study in Central-Italy

Author

D’Alessandro, Francesco, Cazzato, Massimiliano, Laurino, Elenia, Morganti, Riccardo, Bardelli, Marco, Frediani, Bruno, Buongarzone, Claudia, Moroncini, Gianluca, Guiducci, Serena, Cometi, Laura, Benucci, Maurizio, Ligobbi, Francesca, Marotto, Daniela, and Mosca, Marta

Published
2024
Full Text
View/download PDF

5. JAK inhibitors and autoimmune rheumatic diseases

Author

Benucci, Maurizio, Bernardini, Pamela, Coccia, Carmela, De Luca, Riccardo, Levani, Juela, Economou, Alessio, Damiani, Arianna, Russo, Edda, Amedei, Amedeo, Guiducci, Serena, Bartoloni, Elena, Manfredi, Mariangela, Grossi, Valentina, Infantino, Maria, and Perricone, Carlo

Published
2023
Full Text
View/download PDF

6. An Italian Multicenter Study on Anti-NXP2 Antibodies: Clinical and Serological Associations

Author

Fredi, Micaela, Cavazzana, Ilaria, Ceribelli, Angela, Cavagna, Lorenzo, Barsotti, Simone, Bartoloni, Elena, Benucci, Maurizio, De Stefano, Ludovico, Doria, Andrea, Emmi, Giacomo, Fabris, Martina, Fornaro, Marco, Furini, Federica, Giudizi, Maria Grazia, Govoni, Marcello, Ghirardello, Anna, Iaccarino, Luca, Iannone, Fiorenzo, Infantino, Maria, Isailovic, Natasa, Lazzaroni, Maria Grazia, Manfredi, Mariangela, Mathieu, Alessandro, Marasco, Emiliano, Migliorini, Paola, Montecucco, Carlomaurizio, Palterer, Boaz, Parronchi, Paola, Piga, Matteo, Pratesi, Federico, Riccieri, Valeria, Selmi, Carlo, Tampoia, Marilina, Tripoli, Alessandra, Zanframundo, Giovanni, Radice, Antonella, Gerli, Roberto, and Franceschini, Franco

Published
2022
Full Text
View/download PDF

9. Booster dose of SARS-CoV-2 messenger RNA vaccines strengthens the specific immune response of patients with rheumatoid arthritis: A prospective multicenter longitudinal study

Author

Farroni, Chiara, Aiello, Alessandra, Picchianti-Diamanti, Andrea, Laganà, Bruno, Petruccioli, Elisa, Agrati, Chiara, Garbuglia, Anna Rosa, Meschi, Silvia, Lapa, Daniele, Cuzzi, Gilda, Petrone, Linda, Vanini, Valentina, Salmi, Andrea, Altera, Anna Maria Gerarda, Repele, Federica, Grassi, Germana, Bettini, Aurora, Vita, Serena, Mariano, Andrea, Damiani, Arianna, Infantino, Maria, Grossi, Valentina, Manfredi, Mariangela, Niccoli, Laura, Puro, Vincenzo, Rosa, Roberta Di, Salemi, Simonetta, Sesti, Giorgio, Scolieri, Palma, Bruzzese, Vincenzo, Benucci, Maurizio, Cantini, Fabrizio, Nicastri, Emanuele, and Goletti, Delia

Published
2022
Full Text
View/download PDF

11. Soluble urokinase Plasminogen Activator Receptor (suPAR) levels are predictive of COVID-19 severity: an Italian experience

Author

Infantino, Maria, Morena, Lorenza, Di Pietro, Massimo Antonio, Romanin, Benedetta, Cimolato, Barbara, Rocca, Beatrice Anna Luisa, Tunnera, Silvia, Modi, Giulia, Tilli, Marta, Grossi, Valentina, Lari, Barbara, Cerutti, Helena, Tesi, Giulia, Anrò, Valentina, Cartocci, Alessandra, Benucci, Maurizio, Veneziani, Francesca, Casprini, Patrizia, and Manfredi, Mariangela

Published
2022
Full Text
View/download PDF

12. Multiparametric autoantibody analysis: a new paradigm for the diagnosis of connective tissue diseases

Author

Bizzaro, Nicola, Villalta, Danilo, Bini, Vittorio, Migliorini, Paola, Franceschini, Franco, Piantoni, Silvia, Garrafa, Emirena, Riccieri, Valeria, Fioravanti, Antonella, Bellisai, Francesca, Tampoia, Marilina, Fornaro, Marco, Iannone, Florenzo, Ghirardello, Anna, Zen, Margherita, Palterer, Boaz, Parronchi, Paola, Infantino, Maria, Benucci, Maurizio, Rigon, Amelia, Arcarese, Luisa, Del Rosso, Stefania, Canti, Valentina, Bartoloni, Elena, and Gerli, Roberto

Published
2022
Full Text
View/download PDF

14. Cost saving and predictive factors of response to rituximab in rheumatoid arthritis, including the IL-6 promoter gene polymorphism

Author

Quartuccio, Luca, primary, Salvin, Sara, additional, Fabris, Martina, additional, Benucci, Maurizio, additional, Pellerito, Raffaele, additional, Furian, Cristina, additional, Masolini, Paola, additional, Cimmino, Marco, additional, Troncon, Maria Grazia, additional, Guarrera, Giovanni Maria, additional, and De Vita, Salvatore, additional

Published
2024
Full Text
View/download PDF

15. Efficacy and Safety of Filgotinib in Rheumatoid Arthritis Patients Aged over and under 65 Years (ENANTIA-65).

Author

Benucci, Maurizio, Bardelli, Marco, Cazzato, Massimiliano, Bartoli, Francesca, Damiani, Arianna, Li Gobbi, Francesca, Bandinelli, Francesca, Panaccione, Anna, Di Cato, Luca, Niccoli, Laura, Frediani, Bruno, Mosca, Marta, Guiducci, Serena, and Cantini, Fabrizio

Subjects
*OLDER patients, *AGE differences, *MEDIAN (Mathematics), *AGE groups, *THROMBOEMBOLISM
Abstract

Background: According to recent data, the age of patients could represent an important risk factor for MACE (major cardiovascular events), cancer, and VTE (venous thromboembolism) during treatment with JAK inhibitors in rheumatoid arthritis. We decided to analyze the population involved in the ReLiFiRa study by identifying two groups of patients: 65 years or more and less than 65 years of age, evaluating the efficacy and tolerability of 200 mg of Filgotinib daily. Methods: Of the 120 ReLiFiRa patients, 54 were younger than 65 years old and 66 patients were 65 years old or older. The data of efficacy and tolerability of treatment with FIL 200 mg daily for 6 months were evaluated. Results: After six months of treatment, FIL was effective in both age groups. In both groups, the median values of steroid DAS28, CDAI, ERS, PCR, tender joints, swollen joints, VAS, HAQ, PGA patients, and PGA physicians were reduced with a statistically significant difference comparing these values with the baseline values. The difference in age did not impact the effectiveness of the drug. The lipid profile data also did not demonstrate significant differences between the two age groups; however, the comparison between younger vs. older patients' populations regarding the total cholesterol/HDL ratio and LDL/HDL ratio shows a statistically significant difference: total cholesterol/HDL 3.4 (2.12–3.66) vs. 3.64 (3.36–4.13) p = 0.0004, LDL/HDL 1.9 (0.98–2.25) vs. 2.41 (2.04–2.73) p = 0.0002. There are no differences regarding the atherogenic index (LDL-C/HDL-C) and coronary risk index (TC/HDL-C) compared to baseline. Conclusions: After six months of treatment with FIL, the older population group showed a higher level of LDL and a lower level of HDL compared to younger patients. The atherogenic index and coronary risk index are higher in patients aged ≥ 65 years, but interestingly, there were no differences when comparing the 6-month data to baseline values. This condition highlights the impact of typical risk factors that act independently of treatment with Filgotinib. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. Do Ultrasound Lung Abnormalities Correlate to Biomarkers and Male Gender in Rheumatoid Arthritis Patients? A Monocentric Cross-Sectional Study.

Author

Bandinelli, Francesca, Benucci, Maurizio, Mallia, Ilenia, Mauro, Ilaria, Pecani, Nikita, Li Gobbi, Francesca, Manfredi, Mariangela, Guiducci, Serena, Lari, Barbara, Grossi, Valentina, Infantino, Maria, and Giannasi, Gianfranco

Subjects
*LUNGS, *RHEUMATOID arthritis, *BIOMARKERS, *SMOKING, *RHEUMATOID factor, *ULTRASONIC imaging
Abstract

Background: Lung ultrasound (LUS) is a tool of growing interest in Rheumatoid Arthritis (RA) oligo- symptomatic ILD to avoid. Objective: We aimed to evaluate (i) the prevalence of pleural (PLUS) and parenchymal (PAUS) abnormalities in LUS in the RA population and their possible correlation to biomarkers; (ii) the predictivity of gender, smoking habits, previous infections (past COVID-19 tuberculosis), and treatments; (iii) the differences in LUS between sexes. Methods: We collected the data of 155 (15 early and 140 late) RA patients with mild respiratory symptoms, evaluating PLUS and PAUS, in fourteen lung areas and also summing the scores (LUS-T). Results: Only 13/155 (8.4%) were completely negative; LUS correlated to age (all parameters p 0.0001), rheumatoid factor IgM (PLUS p 0.0006, PAUS p 0.02, LUS-T p 0.001) and ACPA (p 0.001, 0.006, 0.001, respectively), and PLUS also correlated to IL6 (p 0.02). The male gender was predictive of all LUS evaluations (p 0.001, 0.05, 0.001, respectively), which were higher than in women (p 0.001, 0.01, 0.001, respectively). Other potential risk factors were independent, except biological treatments, which showed a low predictivity to PLUS (p < 0.05). Conclusions: We can conclude that LUS is a useful technique in RA low respiratory symptoms and correlates with age, the most important RA biomarkers, and male sex. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. ToRaRI (Tofacitinib in Rheumatoid Arthritis a Real-Life experience in Italy): Effectiveness, safety profile of tofacitinib and concordance between patient-reported outcomes and physician's global assessment of disease activity in a retrospective study in Central-Italy

Author

D’Alessandro, Francesco, primary, Cazzato, Massimiliano, additional, Laurino, Elenia, additional, Morganti, Riccardo, additional, Bardelli, Marco, additional, Frediani, Bruno, additional, Buongarzone, Claudia, additional, Moroncini, Gianluca, additional, Guiducci, Serena, additional, Cometi, Laura, additional, Benucci, Maurizio, additional, Ligobbi, Francesca, additional, Marotto, Daniela, additional, and Mosca, Marta, additional

Published
2023
Full Text
View/download PDF

20. COVID 19: a clue from innate immunity

Author

Birra, Domenico, Benucci, Maurizio, Landolfi, Luigi, Merchionda, Anna, Loi, Gabriella, Amato, Patrizia, Licata, Gaetano, Quartuccio, Luca, Triggiani, Massimo, and Moscato, Paolo

Published
2020
Full Text
View/download PDF

22. Real-Life Comparison of Four JAK Inhibitors in Rheumatoid Arthritis (ELECTRA- i Study).

Author

Benucci, Maurizio, Li Gobbi, Francesca, Damiani, Arianna, Russo, Edda, Guiducci, Serena, Manfredi, Mariangela, Lari, Barbara, Grossi, Valentina, and Infantino, Maria

Subjects
*CALPROTECTIN, *RHEUMATOID arthritis, *MAJOR adverse cardiovascular events, *PLASMINOGEN activators, *HERPES zoster
Abstract

Background: Real-world evidence of the efficacy and adverse events of JAK inhibitor treatment (Tofacitinib, Baricitinib, Upadacitinib, and Filgotinib) in rheumatoid arthritis is still limited. Methods: We studied 115 patients from the Rheumatology Unit of S. Giovanni di Dio Hospital affected by D2T-RA, according to the 2010 EULAR criteria. Out of the 115 patients, 17 had been treated with Baricitinib 8 mg/daily, 32 with Filgotinib 200 mg/daily, 21 with Tofacitinib 10 mg/daily, and 45 with Upadacitinib 15 mg/daily. We evaluated the clinical response after 3, 6, and 12 months of treatment and the follow-up from September 2022 to September 2023. All patients were evaluated according to the number of tender joints (NTJs), number of swollen joints (NSJs), visual analog scale (VAS), global assessment (GA), health assessment questionnaire (HAQ), Disease Activity Score (DAS28), and CDAI. Furthermore, laboratory parameters of efficacy and tolerability were evaluated. Results: All treatments demonstrated a statistically significant decrease in the DAS28 and CDAI scores, tender and swollen joint counts, VAS, HAQ, and patient global assessment (PGA) after 3, 6, and 12 months of treatment. All treatments showed similar behavior, and statistically significant decreases in circulating calprotectin, TNFα, and IL-6 were observed for all drugs after 12 months of treatment. In addition, soluble urokinase plasminogen activator receptor (suPAR) values showed significant differences at baseline and after 12 months of treatment for Filgotinib: 4.87 ± 4.53 vs. 3.61 ± 0.9 (0.009) and Upadacitinib: 6.64 ± 7.12 vs. 4.06 ± 3.61 (0.0003), while no statistically significant differences were found for Baricitinib: 3.4 ± 0.1 vs. 3.78 ± 0.1 and Tofacitinib: 3.95 ± 1.77 vs. 2.58 ± 0.1. The TC/HDL-C ratio (atherogenic index) showed significant differences when comparing Baricitinib vs. Filgotinib (0.0012), Filgotinib vs. Tofacitinib (0.0095), and Filgotinib vs. Upadacitinib (0.0001); furthermore, the LDL-C/HDL-C ratio in the Filgotinib group did not change (2.37 ± 0.45 vs. 2.35 ± 2.13 (NS)) after 12 months of treatment. Venous Thrombotic Events (VTEs) and major adverse cardiovascular events (MACEs) accounted for 1% of adverse events after treatment with Baricitinib. Herpes zoster reactivation accounted for 1% of adverse events after treatment with Filgotinib and Tofacitinib, while non-melanoma skin cancer (NMSC) accounted for 1% of adverse events after Upadacitinib treatment. Conclusions: Our real-world data from patients with RA show differences in some laboratory parameters and in the impact of lipid metabolism in JAK inhibitor treatment. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

23. Older Age, a High Titre of Neutralising Antibodies and Therapy with Conventional DMARDs Are Associated with Protection from Breakthrough Infection in Rheumatoid Arthritis Patients after the Booster Dose of Anti-SARS-CoV-2 Vaccine

Author

Picchianti-Diamanti, Andrea, primary, Navarra, Assunta, additional, Aiello, Alessandra, additional, Laganà, Bruno, additional, Cuzzi, Gilda, additional, Salmi, Andrea, additional, Vanini, Valentina, additional, Maggi, Fabrizio, additional, Meschi, Silvia, additional, Matusali, Giulia, additional, Notari, Stefania, additional, Agrati, Chiara, additional, Salemi, Simonetta, additional, Di Rosa, Roberta, additional, Passarini, Damiano, additional, Di Gioia, Valeria, additional, Sesti, Giorgio, additional, Conti, Fabrizio, additional, Spinelli, Francesca Romana, additional, Corpolongo, Angela, additional, Chimenti, Maria Sole, additional, Ferraioli, Mario, additional, Sebastiani, Gian Domenico, additional, Benucci, Maurizio, additional, Li Gobbi, Francesca, additional, Santoro, Anna Paola, additional, Capri, Andrea, additional, Puro, Vincenzo, additional, Nicastri, Emanuele, additional, and Goletti, Delia, additional

Published
2023
Full Text
View/download PDF

24. Pursuing appropriateness in antiphospholipid antibodies testing: Feasibility study with a reflex test approach for anti-β2GPI I domain

Author

Infantino, Maria, primary, Foddai, Silvia, additional, Manfredi, Mariangela, additional, Benucci, Maurizio, additional, Radin, Massimo, additional, Cecchi, Irene, additional, Barinotti, Alice, additional, Aluf, Ofir, additional, Rubini, Elena, additional, Elnaz, Rahbari, additional, Menegatti, Elisa, additional, Roccatello, Dario, additional, and Sciascia, Savino, additional

Published
2023
Full Text
View/download PDF

25. ReLiFiRa (Real Life Filgotinib in Rheumatoid Arthritis): Retrospective Study of Efficacy and Safety in Common Clinical Practice

Author

Benucci, Maurizio, primary, Bardelli, Marco, additional, Cazzato, Massimiliano, additional, Laurino, Elenia, additional, Bartoli, Francesca, additional, Damiani, Arianna, additional, Li Gobbi, Francesca, additional, Panaccione, Anna, additional, Di Cato, Luca, additional, Niccoli, Laura, additional, Frediani, Bruno, additional, Mosca, Marta, additional, Guiducci, Serena, additional, and Cantini, Fabrizio, additional

Published
2023
Full Text
View/download PDF

26. ToRaRI (Tofacitinib in Rheumatoid Arthritis a Real-Life experience in Italy): Effectiveness, safety profile of tofacitinib and concordance between patient-reported outcomes and physician's global assessment of disease activity in a retrospective study in Central-Italy

Author

D'Alessandro, Francesco, Cazzato, Massimiliano, Laurino, Elenia, Morganti, Riccardo, Bardelli, Marco, Frediani, Bruno, Buongarzone, Claudia, Moroncini, Gianluca, Guiducci, Serena, Cometi, Laura, Benucci, Maurizio, Ligobbi, Francesca, Marotto, Daniela, and Mosca, Marta

Subjects
RHEUMATOID arthritis, PHYSICIANS, BIOTHERAPY, BIOLOGICALS, KINASE inhibitors, RHEUMATOLOGISTS, VARICELLA-zoster virus diseases
Abstract

Introduction: The use of Janus Kinase Inhibitors (JAK-Is) in rheumatoid arthritis (RA) has entered in daily practice. In consideration of ORAL-Surveillance trial and the new EULAR recommendations, real-world data are needed to assess Jak-Is safety and effectiveness. The multicenter study presented here aimed to evaluate effectiveness and safety of tofacitinib in a real-life cohort. Methods: A retrospective analysis was performed from September 2021 to December 2022. Data were collected when tofacitinib was started (T0) and after 3 (T3), 6 (T6) and 12 (T12) months of treatment. The primary objective was to analyze the efficacy and safety of tofacitinib. Safety was assessed by recording adverse events (AEs) with and without discontinuation. The secondary objective was to assess the difference between Patient-Reported Outcomes (PROs) and Physician's Global Assessment of disease activity (PhGA). Results: 122 patients were included in the study from the following rheumatology Centers: Pisa, Ancona, Florence (two Centers), Siena, and Sardinia. A statistically significant improvement in DAS-28-CRP, CDAI and SDAI score was observed at T3, T6, compared to baseline (p < 0.001). Improvement was confirmed in patients who reach T12. Patients naïve to bDMARDs showed a shorter remission time and higher remission rates. There was also a statistically significant improvement in PROs compared to baseline (p < 0.001). The improvement was rapid and was consistent with PhGA. The 12-month retention rate for tofacitinib was 89.35%. Reasons to stop tofacitinib were: insufficient response (7), gastrointestinal symptoms (2), infection (1), malignancy (1), Zoster (1), pruritus sine materia (1). Conclusions: Tofacitinib is safe and effective in our RA cohort. It induces higher remission rates in patients naive to bDMARDs, suggesting that there may be a benefit using it as first-line therapy. Additionally, improvement in PROs was consistent with PhGA scores, demonstrating how tofacitinib affects both the objective and subjective components of disease activity. Key Points 1. JAK inhibitors are considered at a similar level as biologic agents in terms of effectiveness. 2. After ORAL-Surveillance results, real-world data are needed to assess the benefit/risk profile of Jaki. 3. Disagreement between patients and physicians has been previously reported with biologic therapy among patients with rheumatoid arthritis, with patients rating disease activity higher than physicians. 4. Jak inhibitors could reduce this discrepancy, due to their mechanism of action. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

27. Management of psoriatic arthritis: a consensus opinion by expert rheumatologists.

Author

D'Angelo, Salvatore, Atzeni, Fabiola, Benucci, Maurizio, Bianchi, Gerolamo, Cantini, Fabrizio, Felice Caporali, Roberto, Carlino, Giorgio, Caso, Francesco, Cauli, Alberto, Ciccia, Francesco, D'Agostino, Maria Antonietta, Dagna, Lorenzo, Dejaco, Christian, Massimiliano Epis, Oscar, Ferrucci, Maria Grazia, Franceschini, Franco, Fusaro, Enrico, Gabini, Marco, Gerli, Roberto, and Giacomelli, Roberto

Published
2023
Full Text
View/download PDF

29. Soluble Urokinase Plasminogen Activator Receptor (suPAR) in Autoimmune Rheumatic and Non Rheumatic Diseases

Author

Manfredi, Mariangela, primary, Van Hoovels, Lieve, additional, Benucci, Maurizio, additional, De Luca, Riccardo, additional, Coccia, Carmela, additional, Bernardini, Pamela, additional, Russo, Edda, additional, Amedei, Amedeo, additional, Guiducci, Serena, additional, Grossi, Valentina, additional, Bossuyt, Xavier, additional, Perricone, Carlo, additional, and Infantino, Maria, additional

Published
2023
Full Text
View/download PDF

31. The Third Dose of BNT162b2 COVID-19 Vaccine Does Not “Boost” Disease Flares and Adverse Events in Patients with Rheumatoid Arthritis

Author

Picchianti Diamanti, Andrea, primary, Navarra, Assunta, additional, Cuzzi, Gilda, additional, Aiello, Alessandra, additional, Salemi, Simonetta, additional, Di Rosa, Roberta, additional, De Lorenzo, Chiara, additional, Vio, Daniele, additional, Sebastiani, Giandomenico, additional, Ferraioli, Mario, additional, Benucci, Maurizio, additional, Li Gobbi, Francesca, additional, Cantini, Fabrizio, additional, Polidori, Vittoria, additional, Simmaco, Maurizio, additional, Cialdi, Esmeralda, additional, Scolieri, Palma, additional, Bruzzese, Vincenzo, additional, Nicastri, Emanuele, additional, D’Amelio, Raffaele, additional, Laganà, Bruno, additional, and Goletti, Delia, additional

Published
2023
Full Text
View/download PDF

32. Correction: Benucci et al. Predicting Loss of Efficacy after Non-Medical Switching: Correlation between Circulating TNF-α Levels and SB4 in Etanercept to SB4 Switchers and Naïve Patients with Rheumatic Disease. J. Pers. Med. 2022, 12, 1174

Author

Benucci, Maurizio, primary, Damiani, Arianna, additional, Bandinelli, Francesca, additional, Russo, Edda, additional, Li Gobbi, Francesca, additional, Grossi, Valentina, additional, Amedei, Amedeo, additional, Infantino, Maria, additional, and Manfredi, Mariangela, additional

Published
2023
Full Text
View/download PDF

33. The Association of uPA, uPAR, and suPAR System with Inflammation and Joint Damage in Rheumatoid Arthritis: suPAR as a Biomarker in the Light of a Personalized Medicine Perspective

Author

Benucci, Maurizio, primary, Damiani, Arianna, additional, Russo, Edda, additional, Guiducci, Serena, additional, Li Gobbi, Francesca, additional, Fusi, Paola, additional, Grossi, Valentina, additional, Amedei, Amedeo, additional, Manfredi, Mariangela, additional, and Infantino, Maria, additional

Published
2022
Full Text
View/download PDF

36. Assessing T-Cell Immunity in Kidney Transplant Recipients with Absent Antibody Production after a 3rd Dose of the mRNA-1273 Vaccine

Author

Infantino, Maria, primary, Tsalouchos, Aris, additional, Russo, Edda, additional, Laudicina, Selene, additional, Grossi, Valentina, additional, Lari, Barbara, additional, Benucci, Maurizio, additional, Stacchini, Lorenzo, additional, Amedei, Amedeo, additional, Casprini, Patrizia, additional, Villalta, Danilo, additional, Dattolo, Pietro Claudio, additional, and Manfredi, Mariangela, additional

Published
2022
Full Text
View/download PDF

37. Comparison of current methods for anti‐dsDNA antibody detection and reshaping diagnostic strategies

Author

Infantino, Maria, primary, Palterer, Boaz, additional, Previtali, Giulia, additional, Alessio, Maria‐Grazia, additional, Villalta, Danilo, additional, Carbone, Teresa, additional, Platzgummer, Stefan, additional, Paura, Giusi, additional, Castiglione, Caterina, additional, Fabris, Martina, additional, Pesce, Giampaola, additional, Porcelli, Brunetta, additional, Terzuoli, Lucia, additional, Bacarelli, Maria‐Romana, additional, Tampoia, Marilina, additional, Cinquanta, Luigi, additional, Brusca, Ignazio, additional, Buzzolini, Francesca, additional, Benucci, Maurizio, additional, Tortora, Matteo, additional, Tronchin, Lorenzo, additional, Guarrasi, Valerio, additional, Soda, Paolo, additional, Manfredi, Mariangela, additional, and Bizzaro, Nicola, additional

Published
2022
Full Text
View/download PDF

38. Circulating immune-complexes of IgG/IgM bound to B2-glycoprotein-I associated with complement consumption and thrombocytopenia in antiphospholipid syndrome

Author

Naranjo, Laura, primary, Stojanovich, Ljudmila, additional, Djokovic, Aleksandra, additional, Andreoli, Laura, additional, Tincani, Angela, additional, Maślińska, Maria, additional, Sciascia, Savino, additional, Infantino, Maria, additional, Garcinuño, Sara, additional, Kostyra-Grabczak, Kinga, additional, Manfredi, Mariangela, additional, Regola, Francesca, additional, Stanisavljevic, Natasa, additional, Milanovic, Milomir, additional, Saponjski, Jovica, additional, Roccatello, Dario, additional, Cecchi, Irene, additional, Radin, Massimo, additional, Benucci, Maurizio, additional, Pleguezuelo, Daniel, additional, Serrano, Manuel, additional, Shoenfeld, Yehuda, additional, and Serrano, Antonio, additional

Published
2022
Full Text
View/download PDF

41. Clinical utility of circulating calprotectin to assist prediction and monitoring of COVID‐19 severity: An Italian study

Author

Infantino, Maria, primary, Manfredi, Mariangela, additional, Alessio, Maria Grazia, additional, Previtali, Giulia, additional, Grossi, Valentina, additional, Benucci, Maurizio, additional, Faraone, Antonio, additional, Fortini, Alberto, additional, Grifoni, Elisa, additional, Masotti, Luca, additional, Russo, Edda, additional, Amedei, Amedeo, additional, FitzGerald, Emily, additional, Albesa, Roger, additional, Norman, Gary L., additional, and Mahler, Michael, additional

Published
2022
Full Text
View/download PDF

42. Current technologies for anti-ENA antibody detection: State-of-the-art of diagnostic immunoassays

Author

Infantino, Maria, primary, Carbone, Teresa, additional, Brusca, Ignazio, additional, Alessio, Maria-Grazia, additional, Previtali, Giulia, additional, Platzgummer, Stefan, additional, Paura, Giusi, additional, Castiglione, Caterina, additional, Fabris, Martina, additional, Pesce, Giampaola, additional, Porcelli, Brunetta, additional, Terzuoli, Lucia, additional, Bacarelli, Maria-Romana, additional, Tampoia, Marilina, additional, Cinquanta, Luigi, additional, Villalta, Danilo, additional, Buzzolini, Francesca, additional, Palterer, Boaz, additional, Pancani, Silvia, additional, Benucci, Maurizio, additional, Manfredi, Mariangela, additional, and Bizzaro, Nicola, additional

Published
2022
Full Text
View/download PDF

43. Predicting Loss of Efficacy after Non-Medical Switching: Correlation between Circulating TNF-α Levels and SB4 in Etanercept to SB4 Switchers and Naïve Patients with Rheumatic Disease

Author

Benucci, Maurizio, primary, Damiani, Arianna, additional, Bandinelli, Francesca, additional, Russo, Edda, additional, Li Gobbi, Francesca, additional, Grossi, Valentina, additional, Amedei, Amedeo, additional, Infantino, Maria, additional, and Manfredi, Mariangela, additional

Published
2022
Full Text
View/download PDF

46. The role of neutralizing antibodies by sVNT after two doses of BNT162b2 mRNA vaccine in a cohort of Italian healthcare workers

Author

Infantino, Maria, primary, Manfredi, Mariangela, additional, Stacchini, Lorenzo, additional, Cosma, Claudia, additional, Grossi, Valentina, additional, Lari, Barbara, additional, Russo, Edda, additional, Amedei, Amedeo, additional, Benucci, Maurizio, additional, Veneziani, Francesca, additional, Casprini, Patrizia, additional, Catalano, Cateno Mario, additional, Cirrincione, Giuseppe, additional, Bonaccorsi, Guglielmo, additional, and Pompetti, Adolfo, additional

Published
2022
Full Text
View/download PDF

47. Therapeutic Potential of Ixekizumab in the Treatment of Ankylosing Spondylitis: A Review on the Emerging Clinical Data

Author

Benucci, Maurizio, Damiani, Arianna, Li Gobbi, Francesca, Grossi, Valentina, Infantino, Maria, Manfredi, Mariangela, Niccoli, Laura, and Cantini, Fabrizio

Subjects
ixekizumab, ankylosing spondylitis, randomized control trials, Review
Abstract

Over the last 20 years, the greatly improved knowledges of underlying pathogenic mechanisms of AS, including the role of tumor necrosis factor (TNF), the interleukin 23/Th17 axis, and interleukin-17 (Il-17), constituted the rationale to develop biologics selectively inhibiting these pathways. For more than 10 years, anti-TNF biologics were successfully employed to treat AS, with marked improvement of signs and symptoms in around 60% of the patients. Recent knowledge of the pathophysiology of spondyloarthritis has highlighted the emerging role of the IL-17/IL-23 axis. New therapies with selective biological drugs have emerged in the treatment of this pathology. In this review, we evaluated the effects of ixekizumab, a new anti–IL-17A, that was licensed both by EMA and FDA in August 2019 for the treatment of ankylosing spondylitis. The review highlights the efficacy and safety data of the 3 randomized controlled trials (COAST V-COAST W-COAST X) and those of the extension to 52 weeks of COAST V and COAST W.

Published
2020

48. Vaccination for SARS-CoV-2 in Patients With Psoriatic Arthritis: Can Therapy Affect the Immunological Response?

Author

Benucci, Maurizio, primary, Damiani, Arianna, additional, Infantino, Maria, additional, Manfredi, Mariangela, additional, Lari, Barbara, additional, Grossi, Valentina, additional, Mariotti, Elena Biancamaria, additional, Corrà, Alberto, additional, Aimo, Cristina, additional, Quintarelli, Lavinia, additional, Verdelli, Alice, additional, Li Gobbi, Francesca, additional, Antiga, Emiliano, additional, and Caproni, Marzia, additional

Published
2022
Full Text
View/download PDF

49. Performance evaluation of four surrogate Virus Neutralization Tests (sVNTs) in comparison to the in vivo gold standard test

Author

Pieri, Massimo, primary, Infantino, Maria, primary, Manfredi, Mariangela, primary, Nuccetelli, Marzia, primary, Grossi, Valentina, primary, Lari, Barbara, primary, Tomassetti, Flaminia, primary, Sarubbi, Serena, primary, Russo, Edda, primary, Amedei, Amedeo, primary, Benucci, Maurizio, primary, Casprini, Patrizia, primary, Stacchini, Lorenzo, primary, Castilletti, Concetta, primary, and Bernardini, Sergio, primary

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results